製品番号: HY-108635

C16-PAF

(別名: PAF (C16))

43 Cited Publications

カスタマーレビュー

Based on 43 publication(s) in Google Scholar

C16-PAF (PAF (C16)), a phospholipid mediator, is a platelet-activating factor and ligand for PAF G-protein-coupled receptor (PAFR). C16-PAF exhibits anti-apoptotic effect and inhibits caspase-dependent death by activating the PAFR. C16-PAF is a potent MAPK and MEK/ERK activator. C16-PAF induces increased vascular permeability.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 99.15%
CAS 番号: 74389-68-7
分子式: C₂₆H₅₄NO₇P
分子量:523.68

保管条件:

-20°C, stored under nitrogen

* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)

C16-PAF 構造式

CAS 番号: 74389-68-7

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性

製品説明

IC₅₀ & Target^[1]^[4]^[5]

Human Endogenous Metabolite

ERK

MEK

p38 MAPK アイソフォーム固有の製品をすべて表示 :

MEK アイソフォーム固有の製品をすべて表示 :

ERK アイソフォーム固有の製品をすべて表示 :

Endogenous Metabolite アイソフォーム固有の製品をすべて表示 :

体外実験

C16-PAF (PAF (C16); 0.5-1.5 μM; for 24 hours) elicits significant concentration-dependent neuronal loss in PAFR^/ but not PAFR^+/+ cultures. C16-PAF (1 μM) elicits neuronal death in PAFR^/ cells infected with EGFP alone^[1].
C16-PAF (1 μM; for 24 hours) activates caspase 7 but not caspase 3 in PAFR^/ neurons^[1].
C16-PAF is synthesized by two distinct pathways; the remodeling pathway and the de novo synthesis pathway. C16-PAF acts by binding to a unique G-protein-coupled seven transmembrane receptor^[2]^[3].
C16-PAF (1-25 μg/ml; 6, 12, 24 h) inhibits M. smegmatis and M. bovis BCG growth in a time-dependent manner^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

Cerebellar granule neurons (CGNs) from PAFR^−/− and PAFR^+/+ mice
Concentration:

0.5-1.5 μM
Incubation Time:

24 hours
Result:

Elicited significant concentration-dependent neuronal loss in PAFR^−/− but not PAFR^+/+ cultures in serum-free media.

Western Blot Analysis^[1]

Cell Line:

CGNs
Concentration:

1 μM
Incubation Time:

24 hours
Result:

Activated caspase 7 but not caspase 3 in PAFR^−/− neurons.

化学情報

CAS 番号 74389-68-7
性状 Oil
分子量 523.68
分子式 C₂₆H₅₄NO₇P
Color White to off-white
SMILES

CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP(OCC[N+](C)(C)C)([O-])=O
別名

PAF (C16)
Structure Classification
- Others
Initial Source
- Endogenous metabolite
- Human Gut Microbiota Metabolites
輸送条件

Room temperature in continental US; may vary elsewhere.
保管条件

-20°C, stored under nitrogen

* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)

Publications (43)

All WBCell Proliferation/Viability AssayIF

Sort by:

Journal Impact Factor

Cell Metab

Nicotinamide metabolism face-off between macrophages and fibroblasts manipulates the microenvironment in gastric cancer. [Abstract]

2024 Jun 18:S1550-4131(24)00189-X. PMID: 38897198
Nat Commun

The CXCL8/MAPK/hnRNP-K axis enables susceptibility to infection by EV-D68, rhinovirus, and influenza virus in vitro. [Abstract]

2025 Feb 17;16(1):1715. PMID: 39962077

C16-PAF purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 17;16(1):1715. [Abstract]

WB was performed to measure the protein levels of pERK1/2 and ERK1/2. C16-PAF (100 nM) facilitates the activation of the MAPK pathway and increases EV-D68 78 replication in CXCL8-silenced cells.

C16-PAF purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 17;16(1):1715. [Abstract]

C16-PAF (100 nM) facilitates the activation of the MAPK pathway and increases EV-D68 replication in CXCL8-silenced cells.
Cell Death Dis

Lactate transmission from hypoxic tumor cells promotes macrophage senescence and M2 polarization via the DNMT1-NHE7 axis to accelerate endometrial cancer progression. [Abstract]

2026 Jan 30;17(1):185. PMID: 41617670
Phytomedicine

Guggulsterone suppresses osteosarcoma progression by inhibiting glycolysis through MAPK signaling pathway. [Abstract]

2025 Aug:144:156949. PMID: 40517691

C16-PAF purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2025 Aug:144:156949. [Abstract]

Western blot analysis of p-ERK1/2, p-MEK, HK2, PKM2, and LDHA levels in 143B and U2R cells treated with C16-PAF (1 µM).
Phytomedicine

Brusatol inhibits malignant phenotypes and lipid metabolism of osteosarcoma cells by regulating PI3K/AKT and MAPK pathways. [Abstract]

2025 Feb 12:139:156464. PMID: 39970856
Phytomedicine

Oleanolic acid inhibits hypoxic tumor-derived exosomes-induced premetastatic niche formation in hepatocellular carcinoma by targeting ERK1/2-NFκB signaling. [Abstract]

2024 Apr:126:155208. PMID: 38387275
J Transl Med

Preclinical evaluation of Mito-LND, a targeting mitochondrial metabolism inhibitor, for glioblastoma treatment. [Abstract]

2023 Aug 7;21(1):532. PMID: 37550679

C16-PAF purchased from MedChemExpress. Usage Cited in: J Transl Med. 2023 Aug 7;21(1):532. [Abstract]

LN229 and U251 cells were treated with 1.25 µM Mito-LND and/or 20 µM C16-PAF for 36 h, then cell viabilities were evaluated by CCK-8 assay.

C16-PAF purchased from MedChemExpress. Usage Cited in: J Transl Med. 2023 Aug 7;21(1):532. [Abstract]

The effects of Mito-LND and/or C16-PAF (20 µM) treatment on the levels of p-ERK1/2, p-p90RSK, Bcl-2 and Bax in LN229 and U251 cells were assessed by western blot analysis.

C16-PAF purchased from MedChemExpress. Usage Cited in: J Transl Med. 2023 Aug 7;21(1):532. [Abstract]

The effects of Mito-LND and/or C16-PAF (20 µM) treatment on the mitochondrial membrane potential, Scale bar: 40 μm.
Proc Natl Acad Sci U S A

2026 Jul 7;123(27):e2523789123. PMID: 42384696
Apoptosis

Promoting effect and immunologic role of secretogranin II on bladder cancer progression via regulating MAPK and NF-κB pathways. [Abstract]

2024 Feb;29(1-2):121-141. PMID: 37848672
Int J Biol Macromol

CircMAPK1-encoded micropeptide circMAPK1-110aa inhibits proliferation and differentiation of goat skeletal muscle satellite cells by suppressing MAPK1/3 phosphorylation. [Abstract]

2026 Apr 27:152258. PMID: 42055358
Diabetes Metab J

Hepatocyte RAP1A Deletion Impairs Lipid Catabolism and Worsens Steatosis via Autophagy Activation. [Abstract]

2025 Nov 24. PMID: 41277000
Cell Mol Gastroenterol Hepatol

Vitamin D receptor activation targets ROS-mediated crosstalk between autophagy and apoptosis in hepatocytes in cholestasis mice. [Abstract]

2023;15(4):887-901. PMID: 36280140
Phytother Res

Poricoic Acid A, an Active Ingredient Extracted From Poria cocos, Inhibits Lung Cancer Cell Growth by Suppressing MEK/ERK Signaling Pathway. [Abstract]

2025 Aug 27. PMID: 40859778
Free Radic Biol Med

Resveratrol induces ferroptosis in triple-negative breast cancer through NEDD4L-mediated GPX4 ubiquitination and degradation. [Abstract]

2025 Aug 1:235:231-247. PMID: 40316059

C16-PAF purchased from MedChemExpress. Usage Cited in: Free Radic Biol Med. 2025 Aug 1:235:231-247. [Abstract]

In SUM159 cells treated with ERK agonist (1 μM C16-PAF) in combination with indicated concentrations of RES for 12 h, the protein levels of p-ERK1/2, ERK1/2, p-NEDD4L, NEDD4L, p-SGK1, SGK1 and GPX4 were measured by western blotting assays.
J Med Chem

Discovery of Novel P2Y14R Inhibitors for Ameliorating Liver Fibrosis by Suppressing Hepatic Stellate Cell Activation. [Abstract]

2025 Nov 13;68(21):23277-23299. PMID: 41178760
Front Immunol

Lactic Acid Fermentation Is Required for NLRP3 Inflammasome Activation. [Abstract]

2021 Mar 29;12:630380. PMID: 33854503
Cell Mol Life Sci

Suppression of Skp2 contributes to sepsis-induced acute lung injury by enhancing ferroptosis through the ubiquitination of SLC3A2. [Abstract]

2024 Jul 30;81(1):325. PMID: 39079969
ACS Appl Nano Mater

2025 Nov 4，8(45):21698–21711.
Eur J Pharmacol

Eupalinolide A attenuates bleomycin-induced pulmonary fibrosis by inhibiting lung fibroblast transition. [Abstract]

2026 Jun 28:1028:179011. PMID: 42178011
Int Immunopharmacol

Isoliquiritigenin alleviates neuropathic pain by reducing microglia inflammation through inhibition of the ERK signaling pathway and decreasing CEBPB transcription expression. [Abstract]

2024 Nov 2;143(Pt 3):113536. PMID: 39488922
Int Immunopharmacol

Glucocorticoids improve the balance of M1/M2 macrophage polarization in experimental autoimmune uveitis through the P38MAPK-MEF2C axis. [Abstract]

2023 Jul:120:110392. PMID: 37262960
Mediators Inflamm

After Traumatic Brain Injury, EPHA4 Enhances Endoplasmic Reticulum Stress to Promote M1 Microglial Polarization Through the MAPK Signaling Pathway. [Abstract]

2026 Jan 22:2026:5595023. PMID: 41583121
Transl Stroke Res

Neutrophil Extracellular Traps Induce Brain Edema Around Intracerebral Hematoma via ERK-Mediated Regulation of MMP9 and AQP4. [Abstract]

2024 Dec 28. PMID: 39733198
J Virol

Membrane protein CRISPR screen identifies RPSA as an essential host factor for porcine epidemic diarrhea virus replication. [Abstract]

2025 Aug 19;99(8):e0064925. PMID: 40736249
Cell Cycle

Inhibition of SGK3 regulates hyperplastic scar development in rats through the MAPK/ERK signaling pathway. [Abstract]

2026 Dec;25(1):1-16. PMID: 41674333
Hum Exp Toxicol

Androgen receptor suppresses inflammatory response of airway epithelial cells in allergic asthma through MAPK1 and MAPK14. [Abstract]

2022 Jan-Dec;41:9603271221121320. PMID: 35982617
Cell Biochem Funct

MEK1 activation enhances the ex vivo proliferation of haematopoietic stem/progenitor cell. [Abstract]

2022 Jan;40(1):79-89. PMID: 34855220
J Cancer

Identification of Quercetin as a Natural MMP1 Inhibitor for Overcoming Cisplatin Resistance in Epithelial Ovarian Cancer. [Abstract]

2025 May 31;16(8):2578-2594. PMID: 40535817
Neuroscience

DCPIB Attenuates Ischemia-Reperfusion Injury by Regulating Microglial M1/M2 Polarization and Oxidative Stress. [Abstract]

2024 May 9:S0306-4522(24)00196-9. PMID: 38734301
Placenta

miR-196a-5p suppresses the MAPK/ERK pathway by targeting HOXA7 to regulate the proliferation and apoptosis of placental trophoblasts in gestational diabetes. [Abstract]

2025 Dec:172:167-178. PMID: 41274131
Tissue Cell

Targeting Siglec-15 mediates mitochondrial retrograde regulation of cervical cancer development. [Abstract]

2024 Dec 31:93:102713. PMID: 39756115
3 Biotech

Suppression of KLF5 targets RREB1 to restrain the proliferation of ovarian cancer cells through ERK/MAPK signaling pathway. [Abstract]

2025 Jan;15(1):4. PMID: 39676889
Theriogenology

RFRP-3 suppresses ovarian granulosa cell function in Tan sheep via dual signaling pathways: PI3K/AKT/mTOR and MAPK/ERK1/2. [Abstract]

2026 Aug:260:117909. PMID: 41924772
Biochim Biophys Acta Gen Subj

Cannabidiol reverts the malignant phenotype of hepatocellular carcinoma cells via the GPR55/TP53/MAPK axis. [Abstract]

2024 May 31:130651. PMID: 38825256
Discov Oncol

Ritanserin suppresses acute myeloid leukemia by inhibiting DGKα to downregulate phospholipase D and the Jak-Stat/MAPK pathway. [Abstract]

2023 Jul 1;14(1):118. PMID: 37392305
Clin Transl Oncol

Filamin C activates MAPK/ERK signaling to facilitate epithelial-mesenchymal transition in bladder cancer. [Abstract]

2026 Jun 16. PMID: 42301608
Pulm Circ

High gestational leucine level dampens WDPCP/MAPK signaling to impair the EMT and migration of cardiac microvascular endothelial cells in congenital heart defects. [Abstract]

2024 Nov 21;14(4):e70013. PMID: 39582775
J Reprod Dev

Role and action mechanisms of tPA in CRH-induced apoptosis of mouse oviductal epithelial and mural granulosa cells. [Abstract]

2024 Aug 7;70(4):238-246. PMID: 38910127
Genes Genomics

TSTA3 promotes the malignant progression of bladder cancer by regulating LAMP2 and MAPK signaling pathway-mediated epithelial-mesenchymal transition. [Abstract]

2026 Jan 14. PMID: 41533307
Stem Cells Dev

ADAMTS2 Mediates Osteogenic Differentiation of Dental Follicle Stem Cells Under Compressive Stress and Inflammation. [Abstract]

2025 Nov 26. PMID: 41313669
Res Sq

2026 Jan 8.
Aging (Albany NY)

USP4 promotes PTC progression by stabilizing LDHA and activating the MAPK and AKT signaling pathway. [Abstract]

2024 Oct 11;16(19):12850-12865. PMID: 39393052
Biomed Pharmacother

Echinatin alleviates sepsis severity through modulation of the NF-κB and MEK/ERK signaling pathways. [Abstract]

2024 Sep 4:179:117359. PMID: 39236479

溶剤 & 溶解度

体外:

DMSO : 100 mg/mL (190.96 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.9096 mL

9.5478 mL

19.0956 mL

5 mM

0.3819 mL

1.9096 mL

3.8191 mL

10 mM

0.1910 mL

0.9548 mL

1.9096 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (4.77 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (4.77 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (4.77 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (273 KB)
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Scott D Ryan, et al. Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons. J Lipid Res. 2008 Oct;49(10):2250-8. [Content Brief]

[2]. Z Honda, et al. Transfected platelet-activating factor receptor activates mitogen-activated protein (MAP) kinase and MAP kinase kinase in Chinese hamster ovary cells. J Biol Chem. 1994 Jan 21;269(3):2307-15. [Content Brief]

[3]. Muhammad S Riaz, et al. Direct Growth Inhibitory Effect of Platelet Activating Factor C-16 and Its Structural Analogs on Mycobacteria. Front Microbiol. 2018 Sep 11;9:1903. [Content Brief]

[4]. Jing Chu, et al. IGHG1 Regulates Prostate Cancer Growth via the MEK/ERK/c-Myc Pathway. Biomed Res Int. 2019 Jul 4;2019:7201562. [Content Brief]

[5]. Nina Bögershausen, et al. RAP1-mediated MEK/ERK pathway defects in Kabuki syndrome. J Clin Invest. 2015 Sep;125(9):3585-99. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.9096 mL	9.5478 mL	19.0956 mL	47.7391 mL
	5 mM	0.3819 mL	1.9096 mL	3.8191 mL	9.5478 mL
	10 mM	0.1910 mL	0.9548 mL	1.9096 mL	4.7739 mL
	15 mM	0.1273 mL	0.6365 mL	1.2730 mL	3.1826 mL
	20 mM	0.0955 mL	0.4774 mL	0.9548 mL	2.3870 mL
	25 mM	0.0764 mL	0.3819 mL	0.7638 mL	1.9096 mL
	30 mM	0.0637 mL	0.3183 mL	0.6365 mL	1.5913 mL
	40 mM	0.0477 mL	0.2387 mL	0.4774 mL	1.1935 mL
	50 mM	0.0382 mL	0.1910 mL	0.3819 mL	0.9548 mL
	60 mM	0.0318 mL	0.1591 mL	0.3183 mL	0.7957 mL
	80 mM	0.0239 mL	0.1193 mL	0.2387 mL	0.5967 mL
	100 mM	0.0191 mL	0.0955 mL	0.1910 mL	0.4774 mL

Keywords

C16-PAF

43 Cited Publications

100 mg お問い合わせ

Subscribe to the

MedChemExpress

Newsletter

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

C16-PAF

Immunology/Inflammation Compound Library

MAPK Compound Library

Metabolism/Protease Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

Human Endogenous Metabolite Compound Library

Anti-Aging Compound Library

Covalent Screening Library

Lipid Compound Library

Oxygen Sensing Compound Library

Anti-Cardiovascular Disease Compound Library

Ferroptosis Compound Library

Pyroptosis Compound Library

Glutamine Metabolism Compound Library

Neuroprotective Compound Library

Anti-Lung Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Neurodegenerative Disease-related Compound Library

Angiogenesis-Related Compound Library

Antidepressant Compound Library

Human Metabolite Library

Osteogenesis Compound Library

Coagulation and Anti-coagulation Compound Library

Pain-Related Compound Library

Animal-Sourced Natural Product Library

Highly Selective Activators Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Covalent Screening Library Plus

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Protein Kinase Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Mass Spectrometry Human Endogenous Metabolite Library

Mass Spectrometry Human Metabolite Library

Natural Product Diversity Scaffold Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

MedChemExpress（MCE）の使用を引用している文献 C16-PAF

p38 MAPK アイソフォーム固有の製品をすべて表示

MEK アイソフォーム固有の製品をすべて表示

ERK アイソフォーム固有の製品をすべて表示

Endogenous Metabolite アイソフォーム固有の製品をすべて表示

生物活性

化学情報

Publications (43)

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

C16-PAF 関連分類

HY-108635 関連分類